Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 2/20 | 0.40 |
| ▸ | LTA4H | P09960 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | DGKA | P23743 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889325 | 0.90 | DGKA (0.42) | ALDH1A1LTA4HLMNADGKA | |
| SCHEMBL7420112 | 0.90 | LTA4H (0.42) | ALDH1A1TOP2ALTA4H | |
| SCHEMBL13755924 | 0.85 | LTA4H (0.39) | ALDH1A1LTA4HLMNASMN1; SMN2 | |
| SCHEMBL19051593 | 0.83 | SMN1; SMN2 (0.43) | ALDH1A1TOP2ALMNASMN1; SMN2 | |
| SCHEMBL889272 | 0.80 | THRA (0.34) | ALDH1A1GLATOP2ALTA4HLMNA | |
| SCHEMBL16638656 | 0.78 | S1PR1 (0.37) | LTA4H | |
| SCHEMBL3007160 | 0.78 | ALDH1A1 (0.37) | ALDH1A1GLALMNAMAPK1 | |
| SCHEMBL10820628 | 0.77 | FAAH (0.44) | ALDH1A1LMNA | |
| SCHEMBL2897271 | 0.77 | HRH4 (0.39) | ALDH1A1 | |
| SCHEMBL16638619 | 0.76 | CAPN1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | ALDH1A1 2506/4885GLA 4487/4885TOP2A 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.